Cost saving analysis of specialized, eHealth-based management of patients receiving oral anticoagulation therapy: Results from the thrombEVAL study

Lisa Eggebrecht, Paul Ludolph, Sebastian Göbel, Marina Panova-Noeva, Natalie Arnold, Markus Nagler, Christoph Bickel, Michael Lauterbach, Roland Hardt, Hugo Ten Cate, Karl J Lackner, Christine Espinola-Klein, Thomas Münzel, Jürgen H Prochaska, Philipp S Wild, Lisa Eggebrecht, Paul Ludolph, Sebastian Göbel, Marina Panova-Noeva, Natalie Arnold, Markus Nagler, Christoph Bickel, Michael Lauterbach, Roland Hardt, Hugo Ten Cate, Karl J Lackner, Christine Espinola-Klein, Thomas Münzel, Jürgen H Prochaska, Philipp S Wild

Abstract

To evaluate the cost-saving of a specialized, eHealth-based management service (CS) in comparison to regular medical care (RMC) for the management of patients receiving oral anticoagulation (OAC) therapy. Costs of hospitalization were derived via diagnosis-related groups which comprise diagnoses (ICD-10) and operation and procedure classification system (OPS), which resulted in OAC-related (i.e. bleeding/ thromboembolic events) and non-OAC-related costs for both cohorts. Cost for anticoagulation management comprised INR-testing, personnel, and technical support. In total, 705 patients were managed by CS and 1490 patients received RMC. The number of hospital stays was significantly lower in the CS cohort compared to RMC (CS: 23.4/100 py; RMC: 68.7/100 py); with the most pronounced difference in OAC-related admissions (CS: 2.8/100 py; RMC: 13.3/100 py). Total costs for anticoagulation management amounted to 101 EUR/py in RMC and 311 EUR/py in CS, whereas hospitalization costs were 3261 [IQR 2857-3689] EUR/py in RMC and 683 [504-874] EUR/py in CS. This resulted in an overall cost saving 2368 EUR/py favoring the CS. The lower frequency of adverse events in anticoagulated patients managed by the telemedicine-based CS compared to RMC translated into a substantial cost-saving, despite higher costs for the specialized management of patients.Trial registration: ClinicalTrials.gov, unique identifier NCT01809015, March 8, 2013.

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Net savings in hospitalisation costs per py for anticoagulation specific and non-specific outcomes.
Figure 2
Figure 2
Median costs of hospitalizations for the five most common ICD-principal diagnoses stratified by healthcare model.
Figure 3
Figure 3
Hospitalisation costs over the study period.

References

    1. Friberg L, Rosenqvist M, Lip GY. Net clinical saving of warfarin in patients with atrial fibrillation: A report from the Swedish atrial fibrillation cohort study. Circulation. 2012;125:2298–2307. doi: 10.1161/circulationaha.111.055079.
    1. Giugliano RP, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2013;369:2093–2104. doi: 10.1056/NEJMoa1310907.
    1. Granger CB, et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2011;365:981–992. doi: 10.1056/NEJMoa1107039.
    1. Patel MR, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011;365:883–891. doi: 10.1056/NEJMoa1009638.
    1. Connolly SJ, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009;361:1139–1151. doi: 10.1056/NEJMoa0905561.
    1. Weitz JI, et al. Trends in prescribing oral anticoagulants in Canada, 2008–2014. Clin. Ther. 2015;37:2506–2514.e2504. doi: 10.1016/j.clinthera.2015.09.008.
    1. Eikelboom JW, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N. Engl. J. Med. 2013;369:1206–1214. doi: 10.1056/NEJMoa1300615.
    1. Cooper GM, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood. 2008;112:1022–1027. doi: 10.1182/blood-2008-01-134247.
    1. Connolly SJ, et al. Saving of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029–2037. doi: 10.1161/circulationaha.107.750000.
    1. Sanden P, Renlund H, Svensson PJ, Sjalander A. Bleeding complications and mortality in warfarin-treated VTE patients, dependence of INR variability and iTTR. Thromb Haemost. 2016 doi: 10.1160/th16-06-0489.
    1. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: A systematic review and metaregression. Chest. 2006;129:1155–1166. doi: 10.1378/chest.129.5.1155.
    1. Prochaska JH, et al. e-Health-based management of patients receiving oral anticoagulation therapy: Results from the observational thrombEVAL study. J. Thromb. Haemost. 2017;15:1375–1385. doi: 10.1111/jth.13727.
    1. Wieloch M, et al. Anticoagulation control in Sweden: Reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur. Heart J. 2011;32:2282–2289. doi: 10.1093/eurheartj/ehr134.
    1. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: Anticoagulation control, patient outcomes, and health care costs. Arch. Intern. Med. 1998;158:1641–1647. doi: 10.1001/archinte.158.15.1641.
    1. Rudd KM, Dier JG. Comparison of two different models of anticoagulation management services with usual medical care. Pharmacotherapy. 2010;30:330–338. doi: 10.1592/phco.30.4.330.
    1. Lafata JE, Martin SA, Kaatz S, Ward RE. Anticoagulation clinics and patient self-testing for patients on chronic warfarin therapy: A cost-effectiveness analysis. J. Thromb. Thrombolysis. 2000;9(Suppl 1):S13–19. doi: 10.1023/A:1018704318655.
    1. Hall D, et al. Health care expenditures and therapeutic outcomes of a pharmacist-managed anticoagulation service versus usual medical care. Pharmacotherapy. 2011;31:686–694. doi: 10.1592/phco.31.7.686.
    1. Aziz F, Corder M, Wolffe J, Comerota AJ. Anticoagulation monitoring by an anticoagulation service is more cost-effective than routine physician care. J. Vasc. Surg. 2011;54:1404–1407. doi: 10.1016/j.jvs.2011.05.021.
    1. Sullivan PW, Arant TW, Ellis SL, Ulrich H. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics. 2006;24:1021–1033. doi: 10.2165/00019053-200624100-00009.
    1. KASSENÄRZTLICHE BUNDESVEREINIGUNG. EINHEITLICHER BEWERTUNGSMASSSTAB-EBM. (2018).
    1. Holbrook A, et al. Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e152S–184S. doi: 10.1378/chest.11-2295.
    1. Lafata JE, Martin SA, Kaatz S, Ward RE. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J. Gen. Intern. Med. 2000;15:31–37. doi: 10.1046/j.1525-1497.2000.01239.x.
    1. Landefeld CS, Anderson PA. Guideline-based consultation to prevent anticoagulant-related bleeding. A randomized, controlled trial in a teaching hospital. Ann. Intern. Med. 1992;116:829–837. doi: 10.7326/0003-4819-116-10-829.
    1. Matchar DB, Samsa GP, Cohen SJ, Oddone EZ, Jurgelski AE. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: Results of the managing anticoagulation services trial. Am. J. Med. 2002;113:42–51. doi: 10.1016/S0002-9343(02)01131-2.
    1. Wilson SJ, et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: A randomized controlled trial. CMAJ. 2003;169:293–298.
    1. Prochaska JH, et al. Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service—Results from the prospective, multi-center, observational cohort study thrombEVAL. BMC Med. 2015;13:14. doi: 10.1186/s12916-015-0268-9.
    1. Gadsboll K, et al. Increased use of oral anticoagulants in patients with atrial fibrillation: Temporal trends from 2005 to 2015 in Denmark. Eur. Heart J. 2017;38:899–906. doi: 10.1093/eurheartj/ehw658.
    1. You JH. Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation—A cost-effectiveness analysis. J. Gen. Intern. Med. 2014;29:438–446. doi: 10.1007/s11606-013-2639-2.
    1. Amin A, et al. Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. J. Thromb. Thrombolysis. 2014;38:150–159. doi: 10.1007/s11239-013-1048-z.
    1. Krejczy M, Harenberg J, Wehling M, Obermann K. Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany. Biomed. Res. Int. 2015;2015:876923. doi: 10.1155/2015/876923.
    1. Pokorney SD, et al. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. Am. Heart J. 2015;170(141–148):148.e141. doi: 10.1016/j.ahj.2015.03.017.
    1. Agarwal, S., Hachamovitch, R. & Menon, V. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. Arch. Intern. Med.172, 623–631; discussion 631–623. 10.1001/archinternmed.2012.121 (2012).
    1. BMG & PKV. Anzahl der Mitglieder und Versicherten der gesetzlichen und privaten Krankenversicherung in den Jahren 2011 bis 2017 (in Millionen). (2018).
    1. Prochaska JH, et al. Evaluation of oral anticoagulation therapy: Rationale and design of the thrombEVAL study programme. Eur. J. Prev. Cardiol. 2015;22:622–628. doi: 10.1177/2047487314527852.
    1. Kobel, C., Thuilliez, J., Bellanger, M. & Pfeiffer, K.-P. in Diagnosis-Related Groups in Europe: Moving Towards Transparency, Efficiency and Quality in Hospitals. (eds R. Busse, A. Geissler, W. Quentin, & M. Wiley) 37–58 (Open University Press, New York, 2011).
    1. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb. Haemost. 1993;69:236–239. doi: 10.1055/s-0038-1651587.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere